RESPONSIFY

Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer

Coordinatore	CHARITE - UNIVERSITAETSMEDIZIN BERLIN    more  Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 contact info Titolo: Ms. Nome: Eveline Cognome: Fräßdorf Email: send email Telefono: +49 30 450576024 Fax: +49 30 450576954
Nazionalità Coordinatore	Germany [DE]
Totale costo	7˙782˙794 €
EC contributo	5˙990˙194 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2011-two-stage
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-02-01   -   2015-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CHARITE - UNIVERSITAETSMEDIZIN BERLIN  Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 contact info Titolo: Ms. Nome: Eveline Cognome: Fräßdorf Email: send email Telefono: +49 30 450576024 Fax: +49 30 450576954	DE (BERLIN)	coordinator	860˙580.00
2	GBG FORSCHUNGS GMBH  Organization address address: Schleussnerstrasse 42 city: NEU-ISENBURG postcode: 63263 contact info Titolo: Ms. Nome: Lejla Cognome: Valjevcic Email: send email Telefono: +496102 7480418 Fax: 4961030000000	DE (NEU-ISENBURG)	participant	883˙838.00
3	Institut Jules Bordet  Organization address city: Brussels postcode: 1000 contact info Titolo: Ms. Nome: Marielle Cognome: Sautois Email: send email Telefono: 3225413214 Fax: 3225380858	BE (Brussels)	participant	778˙200.00
4	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Greta Cognome: Borg-Carbott Email: send email Telefono: +44 203 108 3033 Fax: +44 207 813 2849	UK (LONDON)	participant	670˙348.00
5	SIVIDON DIAGNOSTICS GMBH  Organization address address: NATTERMANNALLEE 1 GEB S19 city: KOLN postcode: 50829 contact info Titolo: Dr. Nome: Georg Cognome: Kox Email: send email Telefono: 4922170000000 Fax: 4922170000000	DE (KOLN)	participant	664˙440.00
6	INSTITUT GUSTAVE ROUSSY  Organization address address: Rue Camille Desmoulins 39 city: VILLEJUIF postcode: 94805 contact info Titolo: Mr. Nome: Arnauld Cognome: Forest Email: send email Telefono: 33142116604 Fax: 33142116160	FR (VILLEJUIF)	participant	427˙000.00
7	DIAXONHIT SA  Organization address address: BOULEVARD MASSENA 65 city: PARIS postcode: 75013 contact info Titolo: Mr. Nome: Herve Cognome: Duchesne De Lamotte Email: send email Telefono: +33 153945249	FR (PARIS)	participant	417˙900.00
8	DNA VISION SA  Organization address address: AVENUE G LEMAITRE 25 city: GOSSELIES postcode: 6041 contact info Titolo: Mr. Nome: Dimitri Cognome: Lhoste Email: send email Telefono: +32 71 34 78 80	BE (GOSSELIES)	participant	397˙173.00
9	UNIVERSITAET BASEL  Organization address address: Petersplatz 1 city: BASEL postcode: 4003 contact info Titolo: Dr. Nome: Matthias Cognome: Schwenkglenks Email: send email Telefono: +41 61 265 76 96 Fax: +41 61 265 76 55	CH (BASEL)	participant	325˙835.60
10	TP21 GMBH  Organization address address: LUISENSTRASSE 14 city: BERLIN postcode: 10117 contact info Titolo: Dr. Nome: Hanno Cognome: Wittig Email: send email Telefono: +49 681 3906718 Fax: +49 681 3906720	DE (BERLIN)	participant	288˙000.00
11	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Ms. Nome: Maria Cognome: Von Witting Email: send email Telefono: +46 8 51775878 Fax: +46 8 51770690	SE (STOCKHOLM)	participant	276˙880.00
12	F. HOFFMANN-LA ROCHE AG  Organization address address: GRENZACHERSTRASSE 124 city: BASEL postcode: 4070 contact info Titolo: Dr. Nome: Stefan Cognome: Scherer Email: send email Telefono: +1 650 467 4643	CH (BASEL)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Individualisation of cancer therapy based on standardized biomarker assays is one of the most demanding challenges in cancer medicine. In the RESPONSIFY consortium, we will integrate information on response prediction from different breast cancer types and methodologies into biomarker tests for targeted therapies in the clinical routine setting. Those tests will be developed for commercialisation using the expertise of the involved SMEs and industrial partners. To reach this aim, we will use different genome based strategies to identify and characterise new biomarkers as well as validate biomarkers from previous projects. Genome based strategies include new molecular techniques such as genome wide next generation sequencing, epigenetics, gene and exon expression analysis, as well as kinome arrays, in-situ proteomics and quantitative PCR using FFPE tissue. A clearly defined marker finding-training-validation-approach will be the backbone of RESPONSIFY to reach a high level of evidence for commercial diagnostic tests. The established therapy stratification criteria will be further validated within clinical trials using the expertise of the clinical study groups. The clinical study group will develop a web-based data integration and processing system to standardise integration of clinical trial data and biomarker results in one system which will be further used for clinical biomarker driven trials. Health economic characteristics of combined testing and treatment strategies will be determined to inform decision makers, using state-of-the-art cost-utility analysis. Optimising the use of current therapy options and avoiding treatments patients will predictably not respond to, may improve cost-utility parameters to levels acceptable for most health systems. For rapid evaluation of response parameters, the major focus will be on neoadjuvant therapy. The RESPONSIFY project will lead to validated tests based on formalin-fixed paraffin embedded tissue to predict resistance'

Introduzione (Teaser)

Over 1 million women are diagnosed with breast cancer every year. Scientists are working to improve clinical outcome and minimise toxicity by designing and validating predictive assays that could form the basis for personalised treatment.